12 results
DEF 14A
NMRA
Neumora Therapeutics Inc.
25 Apr 24
Definitive proxy
4:05pm
Partners, a consulting company, from 2015 to 2016. Ms. Suh began her career in R&D strategy with the Regenerative Medicine group of GlaxoSmithKline
424B4
NMRA
Neumora Therapeutics Inc.
18 Sep 23
Prospectus supplement with pricing info
4:12pm
. Suh began her career in R&D strategy with the Regenerative Medicine group of GlaxoSmithKline, a public pharmaceutical company, in 2014. Ms. Suh holds
S-1/A
NMRA
Neumora Therapeutics Inc.
11 Sep 23
IPO registration (amended)
6:07am
career in R&D strategy with the Regenerative Medicine group of GlaxoSmithKline, a public pharmaceutical company, in 2014. Ms. Suh holds an A.B
S-1
NMRA
Neumora Therapeutics Inc.
25 Aug 23
IPO registration
5:03pm
Partners, a consulting company, from 2015 to 2016. Ms. Suh began her career in R&D strategy with the Regenerative Medicine group of GlaxoSmithKline
DRS/A
NMRA
Neumora Therapeutics Inc.
9 Aug 23
Draft registration statement (amended)
12:00am
, she was a consultant at Trinity Partners, a consulting company, from 2015 to 2016. Ms. Suh began her career in R&D strategy with the Regenerative
DRS/A
r3c3 gs5oyo3bqzyx
30 Jun 23
Draft registration statement (amended)
12:00am
DRS/A
eacr4 n47
2 May 23
Draft registration statement (amended)
12:00am
DRS/A
ed7wwkkrsej
2 Sep 22
Draft registration statement (amended)
12:00am
DRS/A
6gg8 sd3knp7wznugd
10 Jun 22
Draft registration statement (amended)
12:00am
DRS/A
3i1xv u1biiue
2 May 22
Draft registration statement (amended)
12:00am
DRS/A
ln1s0ac5dqxln8
23 Dec 21
Draft registration statement (amended)
12:00am
DRS
licjg sxp
8 Nov 21
Draft registration statement
12:00am
- Prev
- 1
- Next